Core Insights - WuXi AppTec (02359) reported an unaudited interim performance for the six months ending June 30, 2025, with revenue of 20.799 billion RMB, a year-on-year increase of 20.6% [1] - The gross profit reached 9.112 billion RMB, up 36% year-on-year, while the net profit attributable to shareholders was 8.287 billion RMB, reflecting a significant increase of 95.5% [1] - The company proposed an interim dividend of 3.5 RMB per 10 shares [1] Revenue Breakdown - The company’s revenue from ongoing operations was 20.41 billion RMB, with significant contributions from various regions: 14.03 billion RMB from U.S. clients (up 38.4%), 2.33 billion RMB from European clients (up 9.2%), 3.15 billion RMB from Chinese clients (down 5.2%), and 0.9 billion RMB from other regions (up 7.6%) [1] Chemical Business Performance - The chemical business generated revenue of 16.3 billion RMB, marking a year-on-year growth of 33.5% [2] - The small molecule drug discovery segment successfully synthesized and delivered over 440,000 new compounds in the past twelve months [2] - The small molecule development and manufacturing (D&M) segment reported revenue of 8.68 billion RMB, a 17.5% increase year-on-year, with a total of 3,409 molecules in the pipeline as of June 30, 2025 [2] TIDES Business Growth - The TIDES business (oligonucleotides and peptides) experienced rapid growth, with revenue reaching 5.03 billion RMB, a remarkable increase of 141.6% [3] - The backlog of TIDES orders grew by 48.8% year-on-year, with a 12% increase in the number of clients served and a 16% increase in the number of molecules served [3] - The company is expanding its peptide production capacity, expecting the total volume of solid-phase synthesis reactors to exceed 100,000L by the end of 2025 [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 支付2025年中期股息分派 茲提述(i)無錫藥明康德新藥開發股份有限公司（「本公司」）於2025年3月26日刊 發的通函（「通函」）；(ii)於2025年3月26日刊發的2024年股東週年大會（「2024年股 東週年大會」）通告（「2024年股東週年大會通告」）；及(iii)於2025年4月29日刊發 的2024年股東週年大會投票結果公告（「公告」）。除非文義另有所指，否則本公 告已界定的詞語在通函、2024年股東週年大會通告及公告中具有相同涵義。 授權董事會制定並實施本公司2025年中期股息分派方案已於2024年股東週年大 會上獲股東批准。據此，董事會在授權範圍內宣派截至2025年6月30日止六個 月的中期股息（「2025年中期股息分派」）如下：每10股派發現金股息人民幣3.50 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 截至2025年6月30日止六個月未經審計中期業績公告 財務摘要 | | 截至6月30日止六個月 | | | | --- | --- | --- | --- | | | 2025年 | 2024年 | 變動 | | | 人民幣百萬元 | 人民幣百萬元 | | | | （百分比除外）（百分比除外） | | | | 收入 | 20,799.3 | 17,240.9 | 20.6% | | 毛利 | 9,112.2 | 6,700.9 | 36.0% | | 毛利率 | 43.8% | 38.9% | | | 母公司持有者之應佔淨溢利 | 8,287.3 | 4,239.8 | 95.5% | | 母公司持有者之應佔溢利淨利率 | 39.8% | 24.6% | | | 經調整非《國際財務報告準則》之 | | | | | 母公司持有者之應佔淨溢利 ...

Core Viewpoint - WuXi AppTec expects capital expenditures to reach 7-8 billion yuan by 2025, driven by business growth and efficiency improvements [1] - The company anticipates an increase in free cash flow from 4-5 billion yuan to 5-6 billion yuan by 2025 [1] Summary by Category Financial Projections - Expected capital expenditures for 2025 are projected to be between 7 billion and 8 billion yuan [1] - Free cash flow is forecasted to rise from 4 billion-5 billion yuan to 5 billion-6 billion yuan by 2025 [1]

Core Viewpoint - WuXi AppTec reported strong financial performance for the first half of 2025, with significant increases in revenue and profit, driven by a focus on CRDMO business and operational efficiency improvements [1][3][4]. Financial Performance - Total operating revenue reached RMB 20.799 billion, a year-on-year increase of 20.64% [3]. - Total profit amounted to RMB 9.907 billion, reflecting a 96.2% year-on-year growth [3]. - Net profit attributable to shareholders was RMB 8.561 billion, up 101.92% compared to the previous year [3]. - Net profit after deducting non-recurring gains and losses was RMB 5.582 billion, a 26.47% increase [3]. - Net cash flow from operating activities was RMB 7.431 billion, showing a 49.63% rise [3]. Business Segments and Orders - As of June 30, 2025, the company had a backlog of orders amounting to RMB 56.69 billion, a 37.2% increase year-on-year [4]. - Revenue from U.S. clients was RMB 14.03 billion, up 38.4% [4]. - Revenue from European clients was RMB 2.33 billion, a 9.2% increase [4]. - Revenue from Chinese clients was RMB 3.15 billion, down 5.2% [4]. - Revenue from other regions was RMB 0.90 billion, up 7.6% [4]. Future Outlook - The company expects revenue growth for its ongoing business to return to double-digit growth, with an adjusted growth rate of 13%-17% [4]. - Overall revenue guidance for the year has been raised to a range of RMB 42.5 billion to RMB 43.5 billion [4].

证券代码：603259 证券简称：药明康德 公告编号：临 2025-051 无锡药明康德新药开发股份有限公司 2025 年度提质增效重回报行动方案进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 无锡药明康德新药开发股份有限公司（以下简称"公司"或"药明康德"） 为践行"以投资者为本"的发展理念，提升上市公司经营质量、规范治理运作水 平，促进上市公司长期可持续发展、增强投资者回报，维护公司全体股东利益， 公司结合自身发展愿景与战略、经营情况及财务状况，制定了 2025 年度提质增 效重回报行动方案。现将 2025 年上半年度公司落实该行动方案的进展情况报告 如下： 一、 聚焦主营业务，保持公司持续盈利能力 公司为全球医药及生命科学行业提供一体化、端到端的新药研发和生产服务， 在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的"CRDMO"业 务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的 治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试 验研发等领域。 过去 20 年 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-050 无锡药明康德新药开发股份有限公司 关于变更董事会秘书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 无锡药明康德新药开发股份有限公司（以下简称"本公司"）董事会于近日 收到本公司董事会秘书张远舟先生的书面申请报告，张远舟先生因工作调整申请 辞去本公司董事会秘书的职务。相关辞任报告自送达本公司董事会时生效。 | 姓名 | 离任职务 | 离任时间 | | 原定任期 到期日 | 离任原因 | 是否继续在上 市公司及其控 | 具体职务 | 是否存在 未履行完 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 股子公司任职 | （如适用） | 毕的公开 | | | | | | | | | | 承诺 | | | | | | | | | 董事会与 | | | | | 年 2025 | 7 | 2026年5月 | | | 证券合规 | | | 张远舟 ...

二、监事会会议审议情况 （一）审议通过《关于公司 2025 年半年度报告、报告摘要及 2025 年半年度 业绩公告的议案》 证券代码：603259 证券简称：药明康德 公告编号：临 2025-048 无锡药明康德新药开发股份有限公司 第三届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2025 年 7 月 14 日向本公司全体监事发出会议通知及会议材料，以现场结合通讯 表决方式于 2025 年 7 月 28 日在公司会议室召开第三届监事会第十三次会议。本 次监事会会议应出席监事3人，实际出席监事3人，会议由监事会主席Harry Liang He（贺亮）主持。本次监事会符合《中华人民共和国公司法》和《无锡药明康 德新药开发股份有限公司章程》（以下简称"《公司章程》"）关于召开监事会 会议的规定。 （二）审议通过《关于公司 2025 年中期利润分配方案的议案》 本公司监事会认为，公司 2025 年中期利润分配方 ...

证券代码：603259 证券简称：药明康德 公告编号：临 2025-047 无锡药明康德新药开发股份有限公司 第三届董事会第二十二次会议决议公告 一、董事会会议召开情况 无锡药明康德新药开发股份有限公司（以下简称"本公司"或"公司"）于 2025 年 7 月 14 日向本公司全体董事发出会议通知及会议材料，以现场结合通讯 表决方式于 2025 年 7 月 28 日在公司会议室召开第三届董事会第二十二次会议。 本次董事会会议应出席董事 12 人，实际出席董事 12 人，会议由董事长 Ge L（i 李 革）主持。本次董事会符合《中华人民共和国公司法》（以下简称"《公司法》"） 和《无锡药明康德新药开发股份有限公司章程》（以下简称"《公司章程》"） 关于召开董事会会议的规定。 二、董事会会议审议情况 （一）审议通过《关于公司 2025 年半年度报告、报告摘要及 2025 年半年度 业绩公告的议案》 同意《无锡药明康德新药开发股份有限公司 2025 年半年度报告》《无锡药明 康德新药开发股份有限公司 2025 年半年度报告摘要》《无锡药明康德新药开发股 份有限公司 2025 年半年度业绩公告》的相关内容。 上述议案已 ...

Dividend Distribution - The company plans to distribute a cash dividend of RMB 3.5000 per 10 shares to all shareholders, totaling RMB 1,009,797,833.10 (including tax) for the 2025 special dividend plan[6] - For the mid-year profit distribution plan, the company intends to distribute RMB 3.5000 per 10 shares, amounting to RMB 1,003,083,788.00 (including tax) based on the adjusted total share capital of 2,865,953,680 shares[6] Financial Performance - Basic earnings per share increased by 106.16% to CNY 3.01 compared to the same period last year[23] - Net profit attributable to shareholders grew by 101.92% to CNY 8.56 billion, driven by a focus on the CRDMO business model and improved operational efficiency[26] - Operating cash flow increased by 49.63% to CNY 7.43 billion, reflecting enhanced financial management and operational efficiency[24] - Total revenue for the period reached CNY 20.80 billion, representing a 20.64% increase year-over-year[26] - The weighted average return on equity rose by 6.31 percentage points to 13.93%[23] - The net profit after deducting non-recurring gains was CNY 5.58 billion, a 26.47% increase from the previous year[26] Business Operations - The company continues to enhance its CRDMO business model to provide integrated drug development and manufacturing services globally[35] - The company sold part of its stake in WuXi XDC Cayman Inc., contributing significantly to profit growth[26] - The company has maintained its commitment to transparency and has provided detailed risk assessments in the report[8] - The company has confirmed that there are no significant risks that could materially affect its operations during the reporting period[8] Revenue Breakdown - Revenue from continuous operations reached RMB 20.4 billion, with a year-on-year increase of 24.2%[40] - The chemical business generated revenue of RMB 16.3 billion, up 33.5% year-on-year, with over 440,000 new compounds successfully synthesized and delivered[40] - TIDES business revenue surged to RMB 5.03 billion, marking a 141.6% increase year-on-year, with a 48.8% growth in order backlog[40] - The testing business revenue was RMB 2.69 billion, with a slight year-on-year increase of 0.4% in laboratory analysis and testing services[41] - The biological business achieved revenue of RMB 1.25 billion, reflecting a 7.1% year-on-year growth[42] Financial Management - The company reported a total investment of RMB 318.49 million during the reporting period, an increase of 12.81% from RMB 282.32 million in the same period last year[65] - The company's trading financial assets increased by 138.45% to RMB 2.94 billion, up from RMB 1.23 billion in the previous year, mainly due to increased purchases of financial products during the reporting period[60] - Short-term borrowings rose by 366.52% to RMB 5.80 billion from RMB 1.24 billion in the previous year, primarily to supplement operating funds and various investment project needs[60] Investment and Expansion - The company plans to expand its small molecule production capacity, with a total reactor volume expected to exceed 4,000 kL by the end of 2025[52] - The company has initiated the construction of a new R&D and production base in Singapore, with the first phase expected to be operational by 2027[52] - The company is committed to enhancing its capabilities in developing new drug types, including peptides and oligonucleotides, to support global pharmaceutical innovation[50] Risk Management - The company faces risks from potential declines in demand for pharmaceutical R&D services, regulatory changes, intensified competition, and compliance issues[81][82] - The company is closely monitoring the legislative developments regarding the U.S. Biodefense Act, which has not seen any proposals for revival in the current Congress[84] Shareholder Information - The company completed the repurchase of 15,775,377 A-shares on June 20, 2025, and subsequently canceled these shares on June 24, 2025[128] - The total number of shares after the repurchase is 2,872,217,205, a decrease of 15,775,377 shares from the previous total of 2,887,992,582[127] - The largest shareholder, HKSCC NOMINEES LIMITED, holds 387,023,887 shares, representing 13.47% of total shares[133] Legal and Compliance - The company has not faced any violations in decision-making procedures regarding external guarantees[8] - The company has not received any penalties or corrective actions related to legal violations during the reporting period[116] - The company has not disclosed any major contracts or their performance during the reporting period[120] Financial Position - The company's total assets reached approximately RMB 83.82 billion as of June 30, 2025, compared to RMB 80.33 billion as of December 31, 2024, indicating a growth of about 3.1%[149] - The company's cash and cash equivalents increased to approximately RMB 21.49 billion from RMB 18.32 billion, reflecting a growth of about 17.7% year-over-year[149] - The company's total current liabilities increased to approximately RMB 10.18 billion, up from RMB 3.26 billion, primarily due to an increase in short-term borrowings[149] Impairment and Valuation - The company conducts annual impairment tests for goodwill, allocating its carrying amount to asset groups that benefit from the synergies of the business combination[183] - The company recognizes impairment losses for goodwill when the recoverable amount of the asset group is less than its carrying amount[183] Currency and Financial Instruments - Foreign currency transactions are translated at the exchange rate close to the transaction date, with differences recognized in profit or loss unless specific conditions are met[188] - Financial assets and liabilities are initially recognized at fair value, with subsequent measurement based on amortized cost or fair value depending on the classification[193]